A Phase 2/3 interventional study of BNT162b2 and Placebo in SARS-CoV-2 Infection, COVID-19 and Maternal Immunization, sponsored by BioNTech SE. Completed at 90 sites in 5 countries. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-06.
Sponsored by BioNTech SE · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.
Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 20th largest by enrollment, is one of 30 that started in 2021, is one of 5 in phase 2/3, and was the 7th registered.
7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Technical University of Munich · Sites in Austria, Belgium, Germany and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
PharmaJet, Inc. · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 23 · Phase 4 11
First in 2020; this study’s year is marked. 30 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 726 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 575 across the 54 interventional studies. Of the 39 that completed or were terminated, 28 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
35 studies in COVID-19 by BioNTech SE: 2 open now, 2 under way, 1 of them phase 3. Of 31 finished, 25 (81%) have results posted.
Among the 35 studies in COVID-19 by BioNTech SE, this one is the 19th largest by enrollment, is one of 10 that started in 2021, is one of 5 in phase 2/3, and was the 12th registered.
BioNTech SE’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing BNT162 Vaccine in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07730450BioNTech SEA Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | 2027-08-20 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing BNT162 Vaccine in COVID-19, from their registry updates:
Among BioNTech SE’s 35 in COVID-19:
This tab as a report to print or save as PDF → With an account.
Results will be submitted, however please note that data are not yet available for all serology outcome measures.
This will be a Phase 2/3, randomized, placebo-controlled, observer-blind study evaluating the safety, tolerability, and immunogenicity of 30 µg of BNT162b2 or placebo administered in 2 doses, 21 days apart, in approximately 350 healthy pregnant women 18 years of age or older vaccinated at 24 to 34 weeks' gestation. Participants will be randomized 1:1 to receive BNT162b2 or placebo (saline).
The Phase 2 portion of the study will include approximately 200 pregnant women randomized 1:1 to receive BNT162b2 or placebo (saline) at 27 to 34 weeks' gestation. IRC review of safety data through 7 days after the second dose for all Phase 2 participants will be completed.
The Phase 3 portion of this study will assess the safety, tolerability, and immunogenicity of BNT162b2 among pregnant women enrolled at 24 to 34 weeks' gestation.
Maternal participants who originally received placebo will receive BNT162b2 at defined time points as part of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 doses
Biological: BNT162b2
2 doses
Other: Placebo
Intramuscular Injection
Intramuscular Injection
Percentage of Maternal Participants Reporting Local Reactions Within 7 Days After Dose 1
Pain at injection site, redness \& swelling were recorded by participants in an electronic diary (e-diary). Redness \& swelling were measured \& recorded in measuring devise units (range 1 to 21) then converted to cm. 1 measuring device unit = 0.5 cm \& graded as mild: \> 2.0 to 5.0 cm, moderate: \> 5.0 to 10.0 cm, severe: \> 10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis (redness) \& necrosis (swelling). Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity \& grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Grade 4 reactions were classified by the investigator or medically qualified person. Reactions reported as adverse events in the case report form within 7 days after the study vaccination were also included in the analysis. Exact 2-sided 95% confidence interval (CI) was based on Clopper \& Pearson method.
Time frame: From Day 1 to Day 7 after dose 1
Percentage of Maternal Participants Reporting Local Reactions Within 7 Days After Dose 2
Pain at injection site, redness \& swelling were recorded by participants in an e-diary. Redness \& swelling were measured \& recorded in measuring devise units (range 1 to 21) then converted to cm. 1 measuring device unit = 0.5 cm \& graded as mild: \> 2.0 to 5.0 cm, moderate: \> 5.0 to 10.0 cm, severe: \> 10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis (redness) \& necrosis (swelling). Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity \& grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Grade 4 reactions were classified by the investigator or medically qualified person. Reactions reported as adverse events (AEs) in the case report form (CRF) within 7 days after the study vaccination were also included in the analysis. Exact 2-sided 95% CI was based on the Clopper \& Pearson method.
Time frame: From Day 1 to Day 7 after dose 2
Percentage of Maternal Participants Reporting Systemic Events Within 7 Days After Dose 1
Systemic events were recorded by participants in an e-diary. Fever was oral temperature \>= 38 degree Celsius (°C) \& categorized as \>=38.0 to 38.4 °C, \>38.4 to 38.9 °C, \>38.9 to 40.0 °C \& \>40.0 °C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain were graded mild: did not interfere with activity, moderate: some interference with activity \& severe: prevented daily routine activity. Vomiting was graded mild: 1 to 2 times in 24 hours (h), moderate: \>2 times in 24h \& severe: required intravenous hydration. Diarrhea was graded mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h \& severe: 6 or more loose stools in 24h. For all systemic events except fever, Grade 4= emergency room visit or hospitalization. Grade 4 events were classified by the investigator/medically qualified person. Systemic events reported as AEs in the CRF within 7 days after vaccination were also included in analysis. Exact 95% CI was based on Clopper \& Pearson method.
Time frame: From Day 1 to Day 7 after dose 1
Percentage of Maternal Participants Reporting Systemic Events Within 7 Days After Dose 2
Systemic events were recorded by participants in an e-diary. Fever was oral temperature \>= 38 °C \& categorized as \>=38.0 to 38.4 °C, \>38.4 to 38.9 °C, \>38.9 to 40.0 °C \& \>40.0 °C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain were graded mild: did not interfere with activity, moderate: some interference with activity \& severe: prevented daily routine activity. Vomiting was graded mild: 1 to 2 times in 24 h, moderate: \>2 times in 24 h \& severe: required intravenous hydration. Diarrhea was graded mild: 2 to 3 loose stools in 24 h, moderate: 4 to 5 loose stools in 24 h \& severe: 6 or more loose stools in 24 h. For all systemic events except fever, Grade 4= emergency room visit or hospitalization. Grade 4 events were classified by the investigator/medically qualified person. Systemic events reported as AEs in the CRF within 7 days after vaccination were also included in analysis. Exact 95% CI was based on Clopper \& Pearson method.
Time frame: From Day 1 to Day 7 after dose 2
Percentage of Maternal Participants With Adverse Events (AEs) From Dose 1 Through 1 Month After Dose 2 - Blinded Follow-up Period
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From dose 1 on Day 1 through 1 month after dose 2 (approximately 2 months)
Percentage of Maternal Participants Reporting Serious Adverse Events (SAEs) From Dose 1 Through 1 Month After Delivery - Blinded Follow-up Period
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From dose 1 on Day 1 through 1 month after delivery (up to 22 weeks)
Geometric Mean Ratio (GMR) of the SARS-CoV-2 Neutralizing Titers in Pregnant Women to Those in Nonpregnant Women From Study C4591001 (NCT04368728) for Evaluable Immunogenicity Population Without Evidence of Prior SARS-CoV-2 Infection
GMR of SARS-CoV-2 neutralizing titers in pregnant women to those in nonpregnant women from study C4591001 (NCT04368728) for evaluable immunogenicity population without evidence of prior SARS-CoV-2 infection up to 1 month after Dose 2 was reported in this outcome measure. Geometric mean titer (GMT) and 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on student t distribution) and was reported in descriptive section. GMR was reported in statistical analysis section of this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of vaccine to which they were randomized, with Dose 2 received within predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.
Time frame: 1 Month after Dose 2
GMR of SARS-CoV-2 Neutralizing Titers in Pregnant Women to Those in Nonpregnant Women From Study C4591001 (NCT04368728) for Evaluable Immunogenicity Population With and Without Evidence of Prior SARS-CoV-2 Infection
GMR of SARS-CoV-2 neutralizing titers in pregnant women to those in nonpregnant women from study C4591001 (NCT04368728) for evaluable immunogenicity population with and without evidence of prior SARS-CoV-2 infection was reported in this outcome measure. GMT and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the student t distribution) and was reported in the descriptive section. GMR was reported in the statistical analysis section. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.
Time frame: 1 Month after Dose 2
COVID-19 Incidence Per 100 Person-Years of Blinded Follow up in Evaluable Maternal Participants Without Evidence of Prior SARS-CoV-2 Infection
COVID-19 incidence per 100 person-years of blinded follow-up in evaluable maternal participants without evidence of prior SARS-CoV-2 infection prior to 7 days after receipt of Dose 2 was reported in this outcome measure.
Time frame: From 7 days after Dose 2 up to 1 month after delivery (Surveillance time [100 person-year]: BNT162b2- 0.155, Placebo- 0.149)
COVID-19 Incidence Per 100 Person-Years of Blinded Follow up in Evaluable Maternal Participants With or Without Evidence of Prior SARS-CoV-2 Infection
COVID-19 incidence per 100 person-years of blinded follow-up in evaluable maternal participants with or without evidence of prior SARS-CoV-2 infection was reported in this outcome measure.
Time frame: From 7 days after Dose 2 up to 1 month after delivery (Surveillance time [100 person-year]: BNT162b2- 0.270, Placebo- 0.263)
Incidence of Asymptomatic Infection of SARS-CoV-2 Through 1 Month After Delivery in Evaluable Maternal Participants Without Evidence of Prior SARS-CoV-2 Infection
Incidence of asymptomatic infection of SARS-CoV-2 through 1 month after delivery in evaluable maternal participants without evidence of prior SARS-CoV-2 infection prior to the first post-dose 2 N-binding test was reported in this outcome measure.
Time frame: Up to 1 month after delivery (Surveillance time [100 person-year]: BNT162b2- 0.099, Placebo- 0.147)
Geometric Mean Concentration (GMCs) of Full-Length S-Binding Immunoglobulin G (IgG) Levels in Evaluable Maternal Participants
GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMCs of full-length S-binding IgG levels in evaluable maternal participants at baseline, 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.
Time frame: Baseline (before Dose 1), 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery
Geometric Mean Titer (GMTs) of SARS-CoV-2 Neutralizing Titers in Evaluable Maternal Participants
GMTs, and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMTs of SARS-CoV-2 neutralizing titers in evaluable maternal participants at baseline, 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.
Time frame: Baseline (before Dose 1), 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery
Geometric Mean Fold Rise (GMFR) From Before Vaccination to Each Subsequent Time Point After Vaccination for Full-Length S-Binding IgG Levels in Evaluable Maternal Participants
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMFR from before vaccination to each subsequent time point after vaccination for full-length S-binding IgG levels in evaluable maternal participants at 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.
Time frame: From before dose 1 up to 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery
Geometric Mean Fold Rise (GMFR) From Before Vaccination to Each Subsequent Time Point After Vaccination for SARS-CoV-2 Neutralizing Titers in Evaluable Maternal Participants
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMFR from before vaccination to each subsequent time point after vaccination for SARS-CoV-2 neutralizing titers in evaluable maternal participants at 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.
Time frame: From before dose 1 up to 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery
Percentage of Infant Participants Reporting Specific Birth Outcomes
Percentage of infant participants reporting specific birth outcomes (normal, congenital malformation/anomaly, other neonatal problems) were reported in this outcome measure.
Time frame: At birth
Percentage of Infant Participants Reporting Adverse Events From Birth Through 1 Month of Age
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From birth through 1 month of age
Percentage of Infant Participants Reporting Serious Adverse Events (SAE) From Birth Through 6 Months of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From birth through 6 months of age
Percentage of Infant Participants Reporting Adverse Event of Special Interest (AESI) From Birth Through 6 Months of Age
Percentage of infant participants who reported AESI including major congenital anomalies and developmental delay from birth through 6 months of age were reported in this outcome measure. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From birth through 6 months of age
GMCs of Full-Length S-Binding IgG Levels at Birth and 6 Months of Age in Infant Participants Born to Evaluable Maternal Participants
GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMCs of full-length S-binding IgG levels at birth and 6 months of age in infant participants born to evaluable maternal participants was reported in this outcome measure.
Time frame: At birth and 6 months of age
GMFR of Full-Length S-Binding IgG Levels From Birth to 6 Months of Age in Infant Participants Born to Evaluable Maternal Participants
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMFR of full-length S-binding IgG levels from birth to 6 months of age in infant participants born to evaluable maternal participants was reported in this outcome measure.
Time frame: From birth to 6 months of age
This study was conducted in 2 periods-Blinded Period (from Day 1 to 1 month post-delivery) and Unblinded Period (1 to 6 Months Post-Delivery for those maternal participants who initially received BNT162b2 and from first dose of BNT162b2 to 1 month after second dose of BNT162b2 for those maternal participants who initially received placebo).
| Milestone | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo Then BNT162b2 30 mcg | Infant Participants: BNT162b2 30 mcg | Infant Participants: Placebo |
|---|---|---|---|---|
| Started | 174 | 174 | 0 | 0 |
| Vaccination 1 | 173 | 173 | 0 | 0 |
| Vaccination 2 | 170 | 170 | 0 | 0 |
| Completed | 161 | 159 | 0 | 0 |
| Not completed | 13 | 15 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 9 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 |
| Withdrew: Unblinded before 1-month postdelivery visit | 6 | 3 | 0 | 0 |
| Milestone | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo Then BNT162b2 30 mcg | Infant Participants: BNT162b2 30 mcg | Infant Participants: Placebo |
|---|---|---|---|---|
| Started | 167 | 162 | 0 | 0 |
| Vaccination 3 | 0 | 152 | 0 | 0 |
| Vaccination 4 | 0 | 148 | 0 | 0 |
| Completed | 151 | 147 | 0 | 0 |
| Not completed | 16 | 15 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 8 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 3 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 4 | 0 | 0 |
| Withdrew: Other | 3 | 0 | 0 | 0 |
| Milestone | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo Then BNT162b2 30 mcg | Infant Participants: BNT162b2 30 mcg | Infant Participants: Placebo |
|---|---|---|---|---|
| Started | 0 | 0 | 167 | 168 |
| Completed | 0 | 0 | 152 | 139 |
| Not completed | 0 | 0 | 15 | 29 |
| Withdrew: Withdrawal by subject | 0 | 0 | 9 | 17 |
| Withdrew: Lost to follow-up | 0 | 0 | 4 | 10 |
| Withdrew: Death | 0 | 0 | 1 | 1 |
| Withdrew: Other | 0 | 0 | 1 | 1 |
Pain at injection site, redness \& swelling were recorded by participants in an electronic diary (e-diary). Redness \& swelling were measured \& recorded in measuring devise units (range 1 to 21) then converted to cm. 1 measuring device unit = 0.5 cm \& graded as mild: \> 2.0 to 5.0 cm, moderate: \> 5.0 to 10.0 cm, severe: \> 10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis (redness) \& necrosis (swelling). Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity \& grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Grade 4 reactions were classified by the investigator or medically qualified person. Reactions reported as adverse events in the case report form within 7 days after the study vaccination were also included in the analysis. Exact 2-sided 95% confidence interval (CI) was based on Clopper \& Pearson method.
| Percentage of participants | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo |
|---|---|---|
| Redness: Mild | 2.5 (0.7 to 6.2) | 0.6 (0.0 to 3.4) |
| Redness: Moderate | 0.6 (0.0 to 3.4) | 0 (0.0 to 2.2) |
| Redness: Severe | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| Redness: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| Swelling: Mild | 4.3 (1.8 to 8.8) | 0 (0.0 to 2.2) |
| Swelling: Moderate | 0.6 (0.0 to 3.4) | 0 (0.0 to 2.2) |
| Swelling: Severe | 0.6 (0.0 to 3.4) | 0 (0.0 to 2.2) |
| Swelling: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| Pain at the injection site: Mild | 59.0 (51.0 to 66.7) | 9.8 (5.7 to 15.5) |
| Pain at the injection site: Moderate | 23.6 (17.3 to 30.9) | 0 (0.0 to 2.2) |
| Pain at the injection site: Severe | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
Pain at injection site, redness \& swelling were recorded by participants in an e-diary. Redness \& swelling were measured \& recorded in measuring devise units (range 1 to 21) then converted to cm. 1 measuring device unit = 0.5 cm \& graded as mild: \> 2.0 to 5.0 cm, moderate: \> 5.0 to 10.0 cm, severe: \> 10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis (redness) \& necrosis (swelling). Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity \& grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Grade 4 reactions were classified by the investigator or medically qualified person. Reactions reported as adverse events (AEs) in the case report form (CRF) within 7 days after the study vaccination were also included in the analysis. Exact 2-sided 95% CI was based on the Clopper \& Pearson method.
| Percentage of participants | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo |
|---|---|---|
| Redness: Mild | 3.4 (1.1 to 7.7) | 0 (0.0 to 2.5) |
| Redness: Moderate | 2.0 (0.4 to 5.8) | 0 (0.0 to 2.5) |
| Redness: Severe | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| Redness: Grade 4 | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| Swelling: Mild | 4.1 (1.5 to 8.6) | 0.7 (0.0 to 3.8) |
| Swelling: Moderate | 2.7 (0.7 to 6.8) | 0 (0.0 to 2.5) |
| Swelling: Severe | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| Swelling: Grade 4 | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| Pain at the injection site: Mild | 54.7 (46.3 to 62.9) | 12.3 (7.5 to 18.8) |
| Pain at the injection site: Moderate | 19.6 (13.5 to 26.9) | 4.1 (1.5 to 8.7) |
| Pain at the injection site: Severe | 0.7 (0.0 to 3.7) | 0 (0.0 to 2.5) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
Systemic events were recorded by participants in an e-diary. Fever was oral temperature \>= 38 degree Celsius (°C) \& categorized as \>=38.0 to 38.4 °C, \>38.4 to 38.9 °C, \>38.9 to 40.0 °C \& \>40.0 °C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain were graded mild: did not interfere with activity, moderate: some interference with activity \& severe: prevented daily routine activity. Vomiting was graded mild: 1 to 2 times in 24 hours (h), moderate: \>2 times in 24h \& severe: required intravenous hydration. Diarrhea was graded mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h \& severe: 6 or more loose stools in 24h. For all systemic events except fever, Grade 4= emergency room visit or hospitalization. Grade 4 events were classified by the investigator/medically qualified person. Systemic events reported as AEs in the CRF within 7 days after vaccination were also included in analysis. Exact 95% CI was based on Clopper \& Pearson method.
| Percentage of participants | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo |
|---|---|---|
| Fever: >=38.0 to 38.4 deg C (100.4 to 101.1 deg Fahrenheit [F]) | 0.6 (0.0 to 3.4) | 1.2 (0.1 to 4.4) |
| Fever: >38.4 to 38.9 deg C (101.2 to 102.0 deg F) | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| Fever: >38.9 to 40.0 deg C (102.1 to 104.0 deg F) | 0.6 (0.0 to 3.4) | 0.6 (0.0 to 3.4) |
| Fever: >40 deg C (>104.0 deg F) | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| Fatigue/tiredness: Mild | 26.1 (19.5 to 33.6) | 20.9 (14.9 to 27.9) |
| Fatigue/tiredness: Moderate | 23.0 (16.7 to 30.3) | 21.5 (15.4 to 28.6) |
| Fatigue/tiredness: Severe | 0.6 (0.0 to 3.4) | 0.6 (0.0 to 3.4) |
| Fatigue/tiredness: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| Headache: Mild | 20.5 (14.5 to 27.6) | 22.1 (16.0 to 29.2) |
| Headache: Moderate | 11.8 (7.3 to 17.8) | 12.9 (8.2 to 19.0) |
| Headache: Severe | 1.9 (0.4 to 5.3) | 0.6 (0.0 to 3.4) |
| Headache: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| Chills: Mild | 5.0 (2.2 to 9.6) | 5.5 (2.6 to 10.2) |
| Chills: Moderate | 1.9 (0.4 to 5.3) | 0 (0.0 to 2.2) |
| Chills: Severe | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| Chills: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| Vomiting: Mild | 5.0 (2.2 to 9.6) | 6.1 (3.0 to 11.0) |
| Vomiting: Moderate | 0 (0.0 to 2.3) | 3.1 (1.0 to 7.0) |
| Vomiting: Severe | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| Vomiting: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| Diarrhea: Mild | 11.2 (6.8 to 17.1) | 7.4 (3.9 to 12.5) |
| Diarrhea: Moderate | 0.6 (0.0 to 3.4) | 1.2 (0.1 to 4.4) |
| Diarrhea: Severe | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| Diarrhea: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| New or worsened muscle pain: Mild | 6.8 (3.5 to 11.9) | 6.1 (3.0 to 11.0) |
| New or worsened muscle pain: Moderate | 5.6 (2.6 to 10.3) | 5.5 (2.6 to 10.2) |
| New or worsened muscle pain: Severe | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| New or worsened joint pain: Mild | 1.2 (0.2 to 4.4) | 2.5 (0.7 to 6.2) |
| New or worsened joint pain: Moderate | 1.9 (0.4 to 5.3) | 2.5 (0.7 to 6.2) |
| New or worsened joint pain: Severe | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 2.2) |
Systemic events were recorded by participants in an e-diary. Fever was oral temperature \>= 38 °C \& categorized as \>=38.0 to 38.4 °C, \>38.4 to 38.9 °C, \>38.9 to 40.0 °C \& \>40.0 °C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain were graded mild: did not interfere with activity, moderate: some interference with activity \& severe: prevented daily routine activity. Vomiting was graded mild: 1 to 2 times in 24 h, moderate: \>2 times in 24 h \& severe: required intravenous hydration. Diarrhea was graded mild: 2 to 3 loose stools in 24 h, moderate: 4 to 5 loose stools in 24 h \& severe: 6 or more loose stools in 24 h. For all systemic events except fever, Grade 4= emergency room visit or hospitalization. Grade 4 events were classified by the investigator/medically qualified person. Systemic events reported as AEs in the CRF within 7 days after vaccination were also included in analysis. Exact 95% CI was based on Clopper \& Pearson method.
| Percentage of participants | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo |
|---|---|---|
| Fever: >=38.0 to 38.4 deg C (100.4 to 101.1 deg F) | 1.4 (0.2 to 4.8) | 0.7 (0.0 to 3.8) |
| Fever: >38.4 to 38.9 deg C (101.2 to 102.0 deg F) | 0.7 (0.0 to 3.7) | 0 (0.0 to 2.5) |
| Fever: >38.9 to 40.0 deg C (102.1 to 104.0 deg F) | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| Fever: >40 deg C (>104.0 deg F) | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| Fatigue/tiredness: Mild | 15.5 (10.1 to 22.4) | 15.8 (10.3 to 22.7) |
| Fatigue/tiredness: Moderate | 32.4 (25.0 to 40.6) | 18.5 (12.6 to 25.8) |
| Fatigue/tiredness: Severe | 2.0 (0.4 to 5.8) | 0 (0.0 to 2.5) |
| Fatigue/tiredness: Grade 4 | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| Headache: Mild | 25.0 (18.3 to 32.8) | 13.7 (8.6 to 20.4) |
| Headache: Moderate | 14.9 (9.6 to 21.6) | 10.3 (5.9 to 16.4) |
| Headache: Severe | 1.4 (0.2 to 4.8) | 0 (0.0 to 2.5) |
| Headache: Grade 4 | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| Chills: Mild | 4.7 (1.9 to 9.5) | 0.7 (0.0 to 3.8) |
| Chills: Moderate | 7.4 (3.8 to 12.9) | 0 (0.0 to 2.5) |
| Chills: Severe | 0.7 (0.0 to 3.7) | 0 (0.0 to 2.5) |
| Chills: Grade 4 | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| Vomiting: Mild | 8.8 (4.8 to 14.6) | 2.1 (0.4 to 5.9) |
| Vomiting: Moderate | 0 (0.0 to 2.5) | 1.4 (0.2 to 4.9) |
| Vomiting: Severe | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| Vomiting: Grade 4 | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| Diarrhea: Mild | 6.1 (2.8 to 11.2) | 4.1 (1.5 to 8.7) |
| Diarrhea: Moderate | 0 (0.0 to 2.5) | 1.4 (0.2 to 4.9) |
| Diarrhea: Severe | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| Diarrhea: Grade 4 | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| New or worsened muscle pain: Mild | 13.5 (8.5 to 20.1) | 4.8 (1.9 to 9.6) |
| New or worsened muscle pain: Moderate | 12.8 (7.9 to 19.3) | 2.1 (0.4 to 5.9) |
| New or worsened muscle pain: Severe | 0.7 (0.0 to 3.7) | 0 (0.0 to 2.5) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| New or worsened joint pain: Mild | 7.4 (3.8 to 12.9) | 4.8 (1.9 to 9.6) |
| New or worsened joint pain: Moderate | 6.1 (2.8 to 11.2) | 1.4 (0.2 to 4.9) |
| New or worsened joint pain: Severe | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo |
|---|---|---|
| Percentage of Maternal Participants With Adverse Events (AEs) From Dose 1 Through 1 Month After Dose 2 - Blinded Follow-up Period | 23.6 (17.3 to 30.9) | 22.7 (16.5 to 29.9) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo |
|---|---|---|
| Percentage of Maternal Participants Reporting Serious Adverse Events (SAEs) From Dose 1 Through 1 Month After Delivery - Blinded Follow-up Period | 13.0 (8.3 to 19.2) | 14.1 (9.2 to 20.4) |
GMR of SARS-CoV-2 neutralizing titers in pregnant women to those in nonpregnant women from study C4591001 (NCT04368728) for evaluable immunogenicity population without evidence of prior SARS-CoV-2 infection up to 1 month after Dose 2 was reported in this outcome measure. Geometric mean titer (GMT) and 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on student t distribution) and was reported in descriptive section. GMR was reported in statistical analysis section of this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of vaccine to which they were randomized, with Dose 2 received within predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.
| Titer | Maternal Participants: BNT162b2 30 mcg | Non-Pregnant Participants: Study C4591001 |
|---|---|---|
| Geometric Mean Ratio (GMR) of the SARS-CoV-2 Neutralizing Titers in Pregnant Women to Those in Nonpregnant Women From Study C4591001 (NCT04368728) for Evaluable Immunogenicity Population Without Evidence of Prior SARS-CoV-2 Infection | 1109.2 (849.2 to 1448.9) | 1663.7 (1411.5 to 1960.8) |
GMR of SARS-CoV-2 neutralizing titers in pregnant women to those in nonpregnant women from study C4591001 (NCT04368728) for evaluable immunogenicity population with and without evidence of prior SARS-CoV-2 infection was reported in this outcome measure. GMT and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the student t distribution) and was reported in the descriptive section. GMR was reported in the statistical analysis section. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.
| Titer | Maternal Participants: BNT162b2 30 mcg | Non-Pregnant Participants: Study C4591001 |
|---|---|---|
| GMR of SARS-CoV-2 Neutralizing Titers in Pregnant Women to Those in Nonpregnant Women From Study C4591001 (NCT04368728) for Evaluable Immunogenicity Population With and Without Evidence of Prior SARS-CoV-2 Infection | 2198.7 (1618.5 to 2987.0) | 1732.0 (1469.4 to 2041.5) |
COVID-19 incidence per 100 person-years of blinded follow-up in evaluable maternal participants without evidence of prior SARS-CoV-2 infection prior to 7 days after receipt of Dose 2 was reported in this outcome measure.
| Events per 100 person-years | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo |
|---|---|---|
| COVID-19 Incidence Per 100 Person-Years of Blinded Follow up in Evaluable Maternal Participants Without Evidence of Prior SARS-CoV-2 Infection | 12.903 | 13.423 |
COVID-19 incidence per 100 person-years of blinded follow-up in evaluable maternal participants with or without evidence of prior SARS-CoV-2 infection was reported in this outcome measure.
| Events per 100 person-years | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo |
|---|---|---|
| COVID-19 Incidence Per 100 Person-Years of Blinded Follow up in Evaluable Maternal Participants With or Without Evidence of Prior SARS-CoV-2 Infection | 7.407 | 11.407 |
Incidence of asymptomatic infection of SARS-CoV-2 through 1 month after delivery in evaluable maternal participants without evidence of prior SARS-CoV-2 infection prior to the first post-dose 2 N-binding test was reported in this outcome measure.
| Events per 100 person-years | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo |
|---|---|---|
| Incidence of Asymptomatic Infection of SARS-CoV-2 Through 1 Month After Delivery in Evaluable Maternal Participants Without Evidence of Prior SARS-CoV-2 Infection | 40.404 | 68.027 |
GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMCs of full-length S-binding IgG levels in evaluable maternal participants at baseline, 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.
| Units/milliliter (U/mL) | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo |
|---|---|---|
| Before Dose 1 | 2.4 (1.6 to 3.7) | 2.0 (1.4 to 2.8) |
| 2 weeks after Dose 2 | 7802.0 (6273.3 to 9703.2) | 1.8 (1.1 to 3.1) |
| 1 month after Dose 2 | 4281.0 (3234.7 to 5665.7) | 1.8 (1.1 to 2.9) |
| At delivery | 2747.6 (2144.7 to 3520.0) | 1.7 (1.0 to 3.0) |
| 6 months after delivery | 1639.4 (780.1 to 3445.4) | — |
GMTs, and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMTs of SARS-CoV-2 neutralizing titers in evaluable maternal participants at baseline, 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.
| Titer | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo |
|---|---|---|
| Before Dose 1 | 47.6 (41.6 to 54.4) | 43.5 (43.5 to 43.5) |
| 2 weeks after Dose 2 | 1991.8 (1456.3 to 2724.1) | 45.0 (42.0 to 48.3) |
| 1 month after Dose 2 | 1212.6 (855.2 to 1719.4) | 43.5 (43.5 to 43.5) |
| At delivery | 695.7 (500.6 to 966.8) | 43.5 (43.5 to 43.5) |
| 6 months after delivery | 465.4 (168.6 to 1284.5) | — |
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMFR from before vaccination to each subsequent time point after vaccination for full-length S-binding IgG levels in evaluable maternal participants at 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.
| Fold rise | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo |
|---|---|---|
| 2 weeks after Dose 2 | 3618.7 (2489.1 to 5260.7) | 0.9 (0.8 to 1.1) |
| 1 month after Dose 2 | 2276.4 (1545.5 to 3352.9) | 0.9 (0.8 to 1.1) |
| At delivery | 1377.6 (948.6 to 2000.5) | 0.8 (0.6 to 1.0) |
| 6 months after delivery | 650.3 (279.3 to 1514.3) | — |
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMFR from before vaccination to each subsequent time point after vaccination for SARS-CoV-2 neutralizing titers in evaluable maternal participants at 2 weeks after Dose 2, 1 month after Dose 2, at delivery, and 6 months after delivery was reported in this outcome measure. Evaluable immunogenicity population included all participants who were eligible and randomized, received 2 doses of the vaccine to which they were randomized, with Dose 2 received within the predefined window (19-42 days, inclusive, after Dose 1); had at least 1 valid immunogenicity result within an appropriate window 1 month after Dose 2 (28-42 days, inclusive, after Dose 2); and had no other important protocol deviations as determined by the clinician.
| Fold rise | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo |
|---|---|---|
| 2 weeks after Dose 2 | 43.7 (33.9 to 56.4) | 1.0 (1.0 to 1.1) |
| 1 month after Dose 2 | 25.3 (18.9 to 33.9) | 1.0 (1.0 to 1.0) |
| At delivery | 15.6 (12.1 to 20.1) | 1.0 (1.0 to 1.0) |
| 6 months after delivery | 11.3 (5.0 to 25.4) | — |
Percentage of infant participants reporting specific birth outcomes (normal, congenital malformation/anomaly, other neonatal problems) were reported in this outcome measure.
| Percentage of participants | Infant Participants: BNT162b2 30 mcg | Infant Participants: Placebo |
|---|---|---|
| Normal | 91.6 (86.3 to 95.3) | 89.3 (83.6 to 93.5) |
| Congenital malformation/anomaly | 6.0 (2.9 to 10.7) | 3.6 (1.3 to 7.6) |
| Other neonatal problem | 1.8 (0.4 to 5.2) | 6.5 (3.3 to 11.4) |
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Infant Participants: BNT162b2 30 mcg | Infant Participants: Placebo |
|---|---|---|
| Percentage of Infant Participants Reporting Adverse Events From Birth Through 1 Month of Age | 35.3 (27.8 to 43.3) | 37.1 (29.6 to 45.1) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Infant Participants: BNT162b2 30 mcg | Infant Participants: Placebo |
|---|---|---|
| Percentage of Infant Participants Reporting Serious Adverse Events (SAE) From Birth Through 6 Months of Age | 13.5 (8.5 to 19.8) | 15.1 (9.9 to 21.6) |
Percentage of infant participants who reported AESI including major congenital anomalies and developmental delay from birth through 6 months of age were reported in this outcome measure. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Infant Participants: BNT162b2 30 mcg | Infant Participants: Placebo |
|---|---|---|
| Percentage of Infant Participants Reporting Adverse Event of Special Interest (AESI) From Birth Through 6 Months of Age | 5.1 (2.2 to 9.9) | 1.3 (0.2 to 4.5) |
GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMCs of full-length S-binding IgG levels at birth and 6 months of age in infant participants born to evaluable maternal participants was reported in this outcome measure.
| Units/milliliter (U/mL) | Infant Participants: BNT162b2 30 mcg | Infant Participants: Placebo |
|---|---|---|
| At Birth | 5576.4 (4246.2 to 7323.2) | 19.4 (10.2 to 37.0) |
| 6 months of age | 311.1 (235.8 to 410.5) | 22.0 (11.4 to 42.7) |
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMFR of full-length S-binding IgG levels from birth to 6 months of age in infant participants born to evaluable maternal participants was reported in this outcome measure.
| Fold rise | Infant Participants: BNT162b2 30 mcg | Infant Participants: Placebo |
|---|---|---|
| GMFR of Full-Length S-Binding IgG Levels From Birth to 6 Months of Age in Infant Participants Born to Evaluable Maternal Participants | 0.1 (0.0 to 0.1) | 0.6 (0.3 to 1.3) |
Collected over Maternal participants-Local reactions/systemic events: From Day (D) 1 to 7 after dose 1 and 2; SAEs: from dose 1 on D 1 up to 6 months (M) after delivery (approx 10 M) (BNT162b2 30 mcg) and up to 1 M after delivery (approx 5 M) (placebo); placebo then BNT162b2: from Dose 3 up to 1 M after Dose 4 (approx 2 M); other AEs: from dose 1 up to 1 M after dose 2 (approx 2 M); (placebo then BNT162b2): from Dose 3 up to 1 M after Dose 4 (approx 2 M). For infants-SAEs and AESIs: from birth up to 6 M of age. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maternal Participants: BNT162b2 30 mcg (Blinded Phase) | 0/161 (0%) | 21/161 (13%) | 143/161 (88.8%) |
| Maternal Participants: Placebo (Blinded Phase) | 0/163 (0%) | 23/163 (14.1%) | 119/163 (73%) |
| Maternal Participants: Placebo Then BNT162b2 (Unblinded Phase) | 0/144 (0%) | 0/144 (0%) | 21/144 (14.6%) |
| Infant Participants: BNT162b2 30 mcg | 0/156 (0%) | 21/156 (13.5%) | 29/156 (18.6%) |
| Infant Participants: Placebo | 1/159 (0.6%) | 24/159 (15.1%) | 33/159 (20.8%) |
| HIV Positive Maternal Participants: BNT162b2 30 mcg (Blinded Phase) | 0/12 (0%) | 2/12 (16.7%) | 12/12 (100%) |
| HIV Positive Maternal Participants: Placebo (Blinded Phase) | 0/10 (0%) | 4/10 (40%) | 10/10 (100%) |
| HIV Positive Maternal Participants: Placebo Then BNT162b2 (Unblinded Phase) | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| HIV Positive Infant Participants: BNT162b2 30 mcg | 1/11 (9.1%) | 1/11 (9.1%) | 1/11 (9.1%) |
| HIV Positive Infant Participants: Placebo | 0/9 (0%) | 2/9 (22.2%) | 3/9 (33.3%) |
| Event | Maternal Participants: BNT162b2 30 mcg (Blinded Phase) | Maternal Participants: Placebo (Blinded Phase) | Maternal Participants: Placebo Then BNT162b2 (Unblinded Phase) | Infant Participants: BNT162b2 30 mcg | Infant Participants: Placebo | HIV Positive Maternal Participants: BNT162b2 30 mcg (Blinded Phase) | HIV Positive Maternal Participants: Placebo (Blinded Phase) | HIV Positive Maternal Participants: Placebo Then BNT162b2 (Unblinded Phase) | HIV Positive Infant Participants: BNT162b2 30 mcg | HIV Positive Infant Participants: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 0/161 | 1/163 | 0/144 | 0/156 | 0/159 | 0/12 | 0/10 | 0/8 | 0/11 | 1/9 |
| Neonatal pneumoniaInfections and infestations | 0/161 | 0/163 | 0/144 | 1/156 | 1/159 | 0/12 | 0/10 | 0/8 | 0/11 | 1/9 |
| GastroenteritisInfections and infestations | 0/161 | 0/163 | 0/144 | 0/156 | 0/159 | 0/12 | 0/10 | 0/8 | 0/11 | 1/9 |
| DehydrationMetabolism and nutrition disorders | 0/161 | 0/163 | 0/144 | 0/156 | 0/159 | 0/12 | 0/10 | 0/8 | 0/11 | 1/9 |
| Superior sagittal sinus thrombosisNervous system disorders | 0/161 | 0/163 | 0/144 | 0/156 | 0/159 | 0/12 | 0/10 | 0/8 | 0/11 | 1/9 |
| Cephalo-pelvic disproportionPregnancy, puerperium and perinatal conditions | 1/161 | 3/163 | 0/144 | 0/156 | 0/159 | 0/12 | 1/10 | 0/8 | 0/11 | 0/9 |
| Fetal distress syndromePregnancy, puerperium and perinatal conditions | 3/161 | 2/163 | 0/144 | 0/156 | 0/159 | 1/12 | 1/10 | 0/8 | 0/11 | 0/9 |
| Fetal hypokinesiaPregnancy, puerperium and perinatal conditions | 1/161 | 1/163 | 0/144 | 0/156 | 0/159 | 0/12 | 1/10 | 0/8 | 0/11 | 0/9 |
| Failed trial of laborPregnancy, puerperium and perinatal conditions | 0/161 | 0/163 | 0/144 | 0/156 | 0/159 | 0/12 | 1/10 | 0/8 | 0/11 | 0/9 |
| PneumoniaInfections and infestations | 0/161 | 1/163 | 0/144 | 0/156 | 0/159 | 0/12 | 0/10 | 0/8 | 1/11 | 0/9 |
| Event | Maternal Participants: BNT162b2 30 mcg (Blinded Phase) | Maternal Participants: Placebo (Blinded Phase) | Maternal Participants: Placebo Then BNT162b2 (Unblinded Phase) | Infant Participants: BNT162b2 30 mcg | Infant Participants: Placebo | HIV Positive Maternal Participants: BNT162b2 30 mcg (Blinded Phase) | HIV Positive Maternal Participants: Placebo (Blinded Phase) | HIV Positive Maternal Participants: Placebo Then BNT162b2 (Unblinded Phase) | HIV Positive Infant Participants: BNT162b2 30 mcg | HIV Positive Infant Participants: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Injection site pain (PAIN AT INJECTION SITE)General disorders | 138/161 | 30/163 | 13/144 | 0/156 | 0/159 | 12/12 | 4/10 | 0/8 | 0/11 | 0/9 |
| Fatigue (FATIGUE)General disorders | 101/161 | 82/163 | 0/144 | 0/156 | 0/159 | 8/12 | 8/10 | 0/8 | 0/11 | 0/9 |
| Headache (HEADACHE)Nervous system disorders | 85/161 | 72/163 | 0/144 | 0/156 | 0/159 | 7/12 | 7/10 | 0/8 | 0/11 | 0/9 |
| Arthralgia (NEW OR WORSENED JOINT PAIN)Musculoskeletal and connective tissue disorders | 22/161 | 13/163 | 0/144 | 0/156 | 0/159 | 1/12 | 5/10 | 0/8 | 0/11 | 0/9 |
| Myalgia (NEW OR WORSENED MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 53/161 | 26/163 | 0/144 | 0/156 | 0/159 | 5/12 | 3/10 | 0/8 | 0/11 | 0/9 |
| Diarrhea (DIARRHEA)Gastrointestinal disorders | 24/161 | 21/163 | 0/144 | 0/156 | 0/159 | 3/12 | 3/10 | 0/8 | 0/11 | 0/9 |
| Vomiting (VOMITING)Gastrointestinal disorders | 18/161 | 16/163 | 0/144 | 0/156 | 0/159 | 3/12 | 1/10 | 0/8 | 0/11 | 0/9 |
| Chills (CHILLS)General disorders | 28/161 | 10/163 | 2/144 | 0/156 | 0/159 | 1/12 | 1/10 | 0/8 | 0/11 | 0/9 |
| HeadacheNervous system disorders | 2/161 | 2/163 | 7/144 | 0/156 | 0/159 | 0/12 | 0/10 | 1/8 | 0/11 | 0/9 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/161 | 0/163 | 0/144 | 0/156 | 0/159 | 0/12 | 0/10 | 1/8 | 0/11 | 0/9 |
For maternal participants, safety population included all randomized participants who received at least 1 dose of the study intervention. For infant participants, safety population included all infant participants born to maternal participants who received at least 1 dose of the study intervention.
| Age, Customized(Participants) | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo Then BNT162b2 30 mcg | Infant Participants: BNT162b2 30 mcg | Infant Participants: Placebo | Total |
|---|---|---|---|---|---|
| Less than (<) 18 years | 0 | 0 | 167 | 168 | 335 |
| Greater than or equal to (>=) 18 and <= 45 years | 173 | 173 | 0 | 0 | 346 |
| Sex: Female, Male(Participants) | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo Then BNT162b2 30 mcg | Infant Participants: BNT162b2 30 mcg | Infant Participants: Placebo | Total |
|---|---|---|---|---|---|
| Female | 173 | 173 | 85 | 73 | 504 |
| Male | 0 | 0 | 82 | 95 | 177 |
| Ethnicity (NIH/OMB)(Participants) | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo Then BNT162b2 30 mcg | Infant Participants: BNT162b2 30 mcg | Infant Participants: Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 70 | 63 | 65 | 60 | 258 |
| Not Hispanic or Latino | 103 | 110 | 98 | 104 | 415 |
| Unknown or Not Reported | 0 | 0 | 4 | 4 | 8 |
| Race (NIH/OMB)(Participants) | Maternal Participants: BNT162b2 30 mcg | Maternal Participants: Placebo Then BNT162b2 30 mcg | Infant Participants: BNT162b2 30 mcg | Infant Participants: Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 1 | 2 | 5 |
| Asian | 5 | 9 | 3 | 7 | 24 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 47 | 43 | 40 | 40 | 170 |
| White | 117 | 118 | 115 | 104 | 454 |
| More than one race | 1 | 0 | 0 | 6 | 7 |
| Unknown or Not Reported | 2 | 1 | 8 | 9 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in Jul 2022, 16 months.
Results were first posted in Dec 2024, 2 years 4 months after primary completion.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 16 months is above that.
Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BNT162 Vaccine